Current developments in neurology, part II: Advances in the pharmacotherapy of Alzheimer disease, Parkinson's disease, and stroke

Annals of Pharmacotherapy

Volumn 30, Issue 12, 1996, Pages 1446-1451

  Gidal, Barry E ^a,h   Lynn Crismon, M ^b   Wagner, Mary L ^c   Fagan, Susan C ^d   Privitera, Michael D ^e   Dalmady Israel, Christina ^f   Graves, Nina M ^g  

^a UNIVERSITY OF WISCONSIN SCHOOL OF MEDICINE AND PUBLIC HEALTH   (United States)

^b UNIVERSITY OF TEXAS AT AUSTIN   (United States)

^c RUTGERS UNIVERSITY   (United States)

^d WAYNE STATE UNIVERSITY   (United States)

^e UNIVERSITY OF CINCINNATI COLLEGE OF MEDICINE   (United States)

^f MedOutcomes Inc   (United States)

^g UNIVERSITY OF MINNESOTA   (United States)

^h UNIVERSITY OF WISCONSIN MADISON   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CATECHOL METHYLTRANSFERASE INHIBITOR; DOPAMINE RECEPTOR STIMULATING AGENT; MONOAMINE OXIDASE INHIBITOR;

ALZHEIMER DISEASE; CHOLINERGIC ACTIVITY; DOPAMINERGIC TRANSMISSION; DRUG BIOAVAILABILITY; ENZYME INHIBITION; HUMAN; LEUKOCYTE FUNCTION; PARKINSON DISEASE; POSTSYNAPTIC MEMBRANE; PRIORITY JOURNAL; PSYCHOSIS; REVIEW; STROKE;

EID: 8044258358     PISSN: 10600280     EISSN: None     Source Type: Journal    
DOI: 10.1177/106002809603001214     Document Type: Review

References (53)

1. Crismon ML. Tacrine: first drug approved for Alzheimer's disease. Ann Pharmacother 1994;28:744-51.
2. Marin DB, Davis KL. Experimental therapeutics. In: Bloom FE, Kupfer DJ, eds. Psychopharmacology: the fourth generation of progress. New York: Raven Press, 1995:1417-26.
3. Mihara M, Ohnishi A, Tomono Y, Hasegawa J, Shimamura Y, Yamazaki K, et al. Pharmacokinetics of E2020, a new compound for Alzheimer's disease, in healthy male volunteers. Int J Clin Pharmacol Ther Toxicol 1993;31:223-9.
4. Pfizer to file NDAs for new chemical entities through 1997; 10 additional NCEs in clinical trials will sustain wave of two to three NDAs per year in future. FDC Rep 1995;57(Oct 30):11-2.
5. Sramek JJ, Sedman AJ, Reece PA, Hourani J, Bockbrader H, Cutler NR. Safety and tolerability of CI-979 in patients with Alzheimer's disease. Life Sci 1995;57:503-10.
6. Lilly transdermal xanomeline to enter Phase II for Alzheimer's after oral formulation dropped; NK-1 antagonist nearing clinicals for chronic pain. FDC Rep 1995;57(Nov 27):13-4.
7. Wilson AL, Langley LK, Monley J, Bauer T, Rottunda S, McFalls E, et al. Nicotine patches in Alzheimer's disease: pilot study on learning, memory, and safety. Pharmacol Biochem Behav 1995;51:509-14.
8. Parnetti L. Clinical pharmacokinetics of drugs for Alzheimer's disease. Clin Pharmacokinet 1995;29:110-29.
9. Pettegrew JW, Klunk WE, Panchalingam K, Kanfer JN, McClure RJ. Clinical and neurochemical effects of acetyl-L-carnitine in Alzheimer's disease. Neurobiol Aging 1995;16:1-4.
10. Huff FJ, Antuono PG, Delagandara JE, McDonald MA, Cutler NR, Cohen SR, et al. A treatment and withdrawal trial of besipridine in Alzheimer's disease. J Alzheimer's Dis Assoc Disord (in press).
11. Saletu B, Paulus E, Linzmayer L, Anderer P, Semlitsch HV, Grunberger J, et al. Nicergoline in senile dementia of Alzheimer type and multi-infarct dementia: a double-blind, placebo-controlled, clinical and EEG/ERP mapping study. Psychopharmacology 1995;117:385-95.
12. Schneider LS, Tariot PN. Emerging drugs for Alzheimer's disease: mechanisms of action and prospects for cognitive enhancing medications. Med Clin North Am 1994;78:911-34.
13. Eggert AE, Crismon ML, Ereshefsky L. Alzheimer's disease. In: DiPiro JT, Talbert RL, Yee GC, Matzke GR, Wells BG, Posey LM, eds. Pharmacotherapy: a pathophysiologic approach. 3rd ed. Nonvalk, CT: Appleton & Lange 1996:1325-44.
14. Rogers J, Kirby LC, Hempelman SR, Berry DL, McGeer PL, Kaszniak AW, et al. Clinical trial of indomethacin in Alzheimer's disease. Neurology 1993;43:1609-11.
15. Rich JB, Rasmusson DX, Holstein MF, Carson KA, Kawas C, Brandt J. Nonsteroidal antiinflammatory drugs in Alzheimer's disease. Neurology 1995;45:51-5.
16. Honja H, Tanaka K, Kashiwagi T, Urabe M, Okada M, Hayashi M, et al. Senile dementia: Alzheimer's type and estrogen. Horm Metab Res 1995;27:204-7.
17. Ohkura T, Isse K, Akazawa K, Hamamoto M, Yaoi Y, Hagino N. Long-term estrogen replacement therapy in female patients with dementia of the Alzheimer's type. Dementia 1995;6:99-107.
18. Schneider LS, Farlow MR, Henderson VW, Pogoda JM. Effects of estrogen replacement therapy on response to tacrine in patients with Alzheimer's disease. Neurology 1996;46:1580-4.
19. Koller WC, Silver DE, Lieberman A. An algorithm for the management of Parkinson's disease. Neurology 1994;434(suppl 10):S1-52.
20. Quinn N. Drug treatment of Parkinson's disease. BMJ 1995;310:575-9.
21. McDermott MP, Jankovic J, Carter J, Fahn S, Gauthier S, Goetz CG, et al. Factors predictive of the need for levodopa therapy in early untreated Parkinson's disease patients. Arch Neurol 1995;52:565-70.
22. Corboy DL, Wagner ML, Sage JI. Apomorphine for motor fluctuations and freezing in Parkinson's disease. Ann Pharmacother 1995;29:282-8.
23. Korczyn AD, Aviv R. A double-blind study comparing ropinorole and bromocriptine in patients with early Parkinson's disease (abstract). Neurology 1996;46:159.
24. Szegdi A, Wetzel H, Hillert A, Kileser E, Gaebel W, Benkert O. Pramipexole, a novel selective dopamine agonist, in major depression (abstract). Mov Disord 1996;11:166.
25. Inzelberg R, Nisipeanu P, Rabey JM, Katz T, Orlov Y, Kipervasser S. Comparison of cabergoline (CBG) and bromocriptine (BCR) in Parkinson's disease (PD) patients with motor fluctuations (abstract). Neurology 1995;45:A292.
26. Jackson-Lewis V, Muthane U, Fahn S, Przedborski S. Effects of antiparkinsonian drugs on mitochondrial function (abstract). Neurology 1995;45:A291.
27. Hao R, Ebadi M, Han H, Litz J, Pfeiffer RF. Selegiline protects dopaminergic neurons in culture from toxic factor(s) in cerebrospinal fluid of Parkinson's disease patients (abstract). Neurology 1995;45:A251.
28. LeWitt PA. Therapies to extend durations of levodopa action. In: Koller WC, Paulson G, eds. Therapy of Parkinson's disease. New York: Marcel Dekker, Inc., 1995:77-90.
29. Shinotoh H, Caine S, Caine DB. Does selegiline afford neuroprotection? In: Koller WC, Paulson G, eds. Therapy of Parkinson's disease. New York: Marcel Dekker, Inc., 1995:321-9.
30. Lees AJ. Comparison of the therapeutic effects and mortality data of levodopa and levodopa combined with selegiline in patients with early mild Parkinson disease. BMJ 1995;311:1602-7.
31. Lewitt PA, Segel SA, Mistura KL, Schork MA. Symptomatic anti-parkinsonian effects of monoamine oxidase-B inhibition: comparison of selegiline and lazabemide. Clin Neuropharmacol 1993;16:332-7.
32. Nutt JG, Woodward WR. Catechol-O-methyltransferase inhibitors in the treatment of Parkinson's disease. In: Koller WC, Paulson G, eds. Therapy of Parkinson's disease. New York: Marcel Dekker, Inc., 1995:287-97.
33. Ruottinen HM, Rinne UK, Abtila S, Karlsson M, Kyyro T, Gordin A. Entacapone increases levodopa response in a one month double-blind study in parkinsonian patients with fluctuations. J Neurol Neurosurg Psychiatry 1996;60:36-40.
34. Kurth MC, Adler CH, St Hilaire M, Singer C, Waters C, Chernik DA, et al. Tolcapone improves motor function and reduces levodopa requirement in patients with Parkinson's disease (PD) experiencing end-of-dose motor fluctuations (abstract). Neurology 1995;45:A275.
35. Myllyla VV. Tolcapone in PD study group I. Clinical efficacy of tolcapone in L-dopa-treated parkinsonian patients with wearing off phenomenon: a multicenter double-blind study (abstract). Neurology 1995;45:A276.
36. Goetz CG, Stebbins GT. Risk factors for nursing home placement in advanced Parkinson's disease. Neurology 1993;43:2227-9.
37. Goetz CG, Stebbins GT. Mortality and hallucinations in nursing home patients with advanced Parkinson's disease. Neurology 1995;45:669-71.
38. Brewer MA, Kurth SC, Imke SC, Lieberman AN. Safety and effectiveness of clozapine for parkinsonian patients with psychosis (abstract). Neurology 1995;45:A252.
39. Wagner ML, Delfippi JL, Menza MA, Sage JL. Clozapine for the treatment of psychosis in Parkinson's disease: chart review of 49 patients. J Neuropsychiatry Clin Neurosci (in press).
40. Pfeiffer C, Wagner ML. Clozapine therapy for Parkinson's disease and other movement disorders. Am J Hosp Pharm 1994;51:3047-53.
41. Mecco G, Alessandria A, Bonifate V, Giustini P. Risperidone for hallucinations in levodopa treated Parkinson's disease patients. Lancet 1994;343:1370-1.
42. Ford B, Lynch T, Green P. Risperidone in Parkinson's disease (letter). Lancet 1994;344:681.
43. Sherman DG, Dyken ML, Fisher M, Gent M, Harrison M, Hart RG. Antithrombotic therapy for cerebrovascular disorders. Chest 1992;102:529S-37S.
44. Helgason CM, Bolin KM, Hoff JA, Winkler SR, Mangat A, Tortorice KL, et al. Development of aspirin resistance in persons with previous ischemic stroke. Stroke 1994;25:2331-6.
45. Khamashta MA, Cuadrado MJ, Mujic F, Taub NA, Hunt BJ, Hughes GRV. The management of thrombosis in the antiphospholipid-antibody syndrome. N Engl J Med 1995;332:993-7.
46. Chamorro A, Vila N, Saiz A, Alday M, Tolosa E. Early anticoagulation after large cerebral embolic infarction. A safety study. Neurology 1995;45:861-5.
47. Brott TG, Haley EC, Levy DE, Barsan W, Broderick J, Sheppard GL, et al. Urgent therapy for stroke. Part 1. Pilot study of tissue plasminogen activator administered within 90 minutes. Stroke 1992;23:632-40.
48. Hommel M, Boissel JP, Cornu C, Boutitie F, Lees KR, Bosson G, et al. Termination of trial of streptokinase in severe acute ischaemic stroke (letter). Lancet 1995;345:57.
49. The Multicenter Acute Stroke Trial - Europe Study Group. Thrombolytic therapy with streptokinase in acute ischemic stroke. N Engl J Med 1996;335:145-50.
50. The National Institute for Neurological Disorders and Stroke rt-PA Stroke Study Group. Tissue plasminogen activator for acute ischemic stroke. N Engl J Med 1995;333:1581-7.
51. Grotta J, Clark W, Coull B, Pettigrew LC, Mackay B, Goldstein LB, et al. Safety and tolerability of the glutamate antagonist CGS 19755 (selfotel) in patients with acute ischemic stroke. Results of a Phase Ha randomized trial. Stroke 1995;26:602-5.
52. Albers GW, Atkinson RP, Kelley RE, Rosenbaum DM on behalf of the Dextrophan Study Group. Safety, tolerability, and pharmacokinetics of the N-methyl-D-aspartate antagonist dextrorphan in patients with acute stroke. Stroke 1995;25:254-8.
53. Scheinberg P. The biologic basis for the treatment of acute stroke. Neurology 1991;41:1867-73.